Our Latest News - BUHLMANN

BUHLMANN News

BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BÜHLMANN fCAL turbo and fPELA turbo Assays

Amherst NH, September 2024- BÜHLMANN Laboratories AG, a leading manufacturer of specialty, high-quality in-vitro diagnostic and research assays, is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay on their clinical chemistry analyzers (AU480, AU680, AU5800, and DxC 700 AU) with
Continue Reading

AMLI 2024 Recap for BUHLMANN Diagnostics Corp

Key Highlights BUHLMANN Diagnostics Corp proudly participated in the 37th Annual Meeting of the Association of Medical Laboratory Immunologists (AMLI) from August 16-19, 2024, in Nashville, Tennessee. This event was a significant platform for showcasing our latest advancements and contributions to medical laboratory immunology. AMLI 2024 Assays Offerings Our booth showcased a comprehensive immunology assay
Continue Reading

BUHLMANN Diagnostics Corp’s ADLM 2024 Recap

Key Highlights We are thrilled to share the highlights of our successful participation in the Association for Diagnostics and Laboratory Medicine (ADLM) 2024 Annual Meeting & Clinical Lab Expo, held from July 28 to August 1 in Chicago, IL. ADLM 2024 Assays Offerings Our booth showcased our extensive range of fecal calprotectin (fCAL) products, the
Continue Reading

BUHLMANN Diagnostic Corp – New Collaboration with Beckman Coulter

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

Continue Reading

BUHLMANN Diagnostics Corp Recap from DDW 2024

Key Highlights BUHLMANN Diagnostics Corp is excited to share highlights from our participation at Digestive Disease Week (DDW) 2024,  held May 18-21 in Washington, D.C.  Here is a brief overview of our assays offerings and the innovative research we presented. DDW 2024 Assays Offerings At BUHLMANN,  we offer the broadest range of fecal calprotectin (fCAL)
Continue Reading

LabSense News Q3 2024 Edition

In this LabSense News Q3 2024 we're covering KLAR Partners Acquires BÜHLMANN Laboratories AG, New Partnership-Worldwide Collaboration with Beckman Coulter Dx, Poster Corner- BÜHLMANN posters from IFCC WorldLab 2024, Recent & Upcoming Meetings- IFCC WorldLab, ADLM, AMLI. 
Continue Reading

CALEX Cap Updates- Extended Stability, Training Video & CALEX Cap 4.0

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718 & K232057): FDA 510(k) cleared. For in vitro Diagnostic Use. BÜHLMANN fPELA® turbo is FDA 510(k) Exempt. For in vitro Diagnostic Use. CPT Code: Pancreatic Elastase- 123234 CALEX® Cap Updates CALEX Cap 4.0- Improved Total Laboratory Automation (TLA), or Block Automation & Seamless Integration TLA Compatibility: CALEX®Cap 4.0 integrates smoothly with
Continue Reading

LabSense News Q2 2024 Edition

In this "Q2 2024 Edition" we introduced CALEX Cap Updates- Extended Stability, Training Video & CALEX Cap 4.0, Poster Corner- BUHLMANN posters from ECCO & AAAAI 2024 and Recent & Upcoming Meetings- DDW & 2024. 
Continue Reading

Visit BUHLMANN @ AMLI 2024 (LIVE)

AMLI 2024 Assay Offering: BUHLMANN is proud to partner with this event. We offer a comprehensive Immunology assay product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications. Visit www.buhlmannlabs.com or email info@buhlmannlabs.com for more information.   AMLI 2024 37th AMLI Annual Meeting Aug 16-19,
Continue Reading

Visit BUHLMANN at ADLM 2024 (formerly AACC)

Book a Meeting ADLM 2024 Assays Offerings Assays Offerings: BUHLMANN Diagnostic Corp (BDC), offers the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including FDA cleared and Research Use Only (RUO) kits. These fCAL related tests include FDA 510(k) cleared BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo & CALEX® Cap;
Continue Reading